Mesenchymal Stem Cells Promote Matrix Metalloproteinase Secretion By Cardiac Fibroblasts And Reduce Cardiac Ventricular Fibrosis After Myocardial Infarction.
Abstract
Recent studies showed that mesenchymal stem cells (MSCs) transplantation significantly decreased cardiac fibrosis. However, the mechanisms involved in these effects are still poorly understood. In this work, we investigated whether the antifibrotic properties of MSCs involve the regulation of matrix metalloproteinases (MMPs) and matrix metalloproteinase endogenous inhibitor (TIMPs) production by cardiac fibroblasts.In vitro experiments showed that conditioned medium from MSCs decreased viability, alpha-SMA expression and collagen secretion of cardiac fibroblasts. These effects were concomitant to the stimulation of MMP-2/MMP-9 activities and MT1-MMP expression. Experiments performed with fibroblasts from MMP2-/- mice demonstrated that MMP2 plays a preponderant role in preventing collagen accumulation upon incubation with conditioned-medium from MSCs. Interestingly, we found that MSC-conditioned medium also decreased the expression of TIMP2 in cardiac fibroblasts. In vivo studies showed that intracardiac injection of MSCs in a rat model of post-ischemic heart failure induced a significant decrease in ventricular fibrosis. This effect was associated with the improvement of morphological and functional cardiac parameters.In conclusion, we showed that MSCs modulate the phenotype of cardiac fibroblasts and their ability to degrade extracellular matrix. These properties of MSCs open new perspective for understanding of the mechanisms of action of MSCs and anticipate their potential therapeutic or side effects.